Abstract | BACKGROUND: METHODS: RESULTS: We found that the immunotoxin BW-2 specifically killed HuD-positive human SCLC and NB cancer cells at very low concentrations in vitro. Moreover, intratumoral immunotoxin therapy in a nude mouse model of human SCLC (n = 6) significantly reduced local tumor progression without causing toxicity. When the same intratumoral immunotoxin protocol was applied to an immunocompetent A/J mouse model of NB, significant inhibition of local tumor growth was also observed. In neuroblastoma allografted A/J mice (n = 5) treated twice with intratumoral immunotoxin, significant tumor regression occurred in over 80% of the animals and their duration of tumor response was significantly prolonged. CONCLUSIONS: Our study suggests that anti-HuD based immunotoxin therapy may prove to be an effective alternative treatment for patients with SCLC and NB.
|
Authors | Debra Ehrlich, Bo Wang, Wei Lu, Peter Dowling, Ruirong Yuan |
Journal | Journal of hematology & oncology
(J Hematol Oncol)
Vol. 7
Pg. 91
(Dec 19 2014)
ISSN: 1756-8722 [Electronic] England |
PMID | 25523825
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Antibodies, Monoclonal
- ELAV Proteins
- ELAV-Like Protein 4
- Elavl4 protein, mouse
- Immunotoxins
- Ribosome Inactivating Proteins, Type 1
- Streptavidin
- Saporins
|
Topics |
- Animals
- Antibodies, Monoclonal
(chemistry, immunology, pharmacology)
- ELAV Proteins
(immunology)
- ELAV-Like Protein 4
- Humans
- Immunotherapy
(methods)
- Immunotoxins
(chemistry, pharmacology)
- Lung Neoplasms
(drug therapy, immunology)
- Male
- Mice
- Mice, Nude
- Neuroblastoma
(drug therapy, immunology)
- Prognosis
- Ribosome Inactivating Proteins, Type 1
(chemistry, pharmacology)
- Saporins
- Small Cell Lung Carcinoma
(drug therapy, immunology)
- Streptavidin
(chemistry, pharmacology)
- Xenograft Model Antitumor Assays
|